Abstract 3225: Cellular and in vivo models for the analyses of B-Raf and c-Src inhibitors

Cytosolic kinases c-Src and B-Raf represent proto-oncogenes of which mutant or overexpressed variants have been shown to cause cancer. Efforts are taken to develop inhibitors specifically addressing these kinases, some of which have already been approved such as Src inhibitor Dasatinib and BRaf inhibitor Sorafenib. In the current study we have generated cellular systems to allow for the analyses of Src and BRaf inhibitors in kinase specific cellular phosphorylation assays as well as in subcutaneous in vivo models. For both kinases we are introducing in vivo models allowing for regulatable kinase activity and thereby regulatable, kinase dependent tumor growth. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3225.